Table 1 Patient demographic and disease characteristics
Total | C1750 mg/m2 | C1500 mg/m2 | |
|---|---|---|---|
n = 49 | n = 19 | n = 30 | |
Age at registration, median (IQ range) | 63 (55, 67) | 64 (52, 68) | 62 (55, 65) |
Gender, n (%) | |||
Female | 31 (63.3) | 11 (57.9) | 20 (66.7) |
Male | 18 (36.7) | 8 (42.1) | 10 (33.3) |
Ethnicity, n (%) | |||
European | 47 (96.0) | 18 (94.7) | 29 (96.7) |
Maori | 1 (2.0) | 1 (5.3) | 0 (0.0) |
Other | 1 (2.0) | 0 (0.0) | 1 (3.3) |
Histology, n (%) | |||
Adenocarcinoma - NOS | 20 (40.8) | 7 (36.8) | 13 (43.3) |
Adenocarcinoma - poorly differentiated | 4 (8.2) | 2 (10.5) | 2 (6.7) |
Adenocarcinoma - moderately differentiated | 17 (34.7) | 9 (47.4) | 8 (26.7) |
Adenocarcinoma - well differentiated | 1 (2.0) | 1 (5.3) | 0 (0.0) |
Mucinious | 7 (14.3) | 0 (0.0) | 7 (23.3) |
Disease Status, n (%) | |||
Distant metastases only | 41 (83.7) | 17 (89.5) | 24 (80.0) |
Local recurrence | 5 (10.2) | 2 (10.5) | 3 (10.0) |
Distant metastases and local recurrence | 3 (6.1) | 0 (0.0) | 3 (10.0) |
Prior Anticancer Treatment, n (%) | |||
Prior Adjuvant Chemotherapy | 11 (22.4) | 5 (26.3) | 6 (20.0) |
Radiotherapy | 8 (16.3) | 3 (15.8) | 5 (16.7) |
Surgery | 44 (89.8) | 17 (89.5) | 27 (90.0) |
WHO Performance Status, n (%) | |||
0 | 42 (85.7) | 18 (94.7) | 24 (80.0) |
1 | 7 (14.3) | 1 (5.3) | 6 (20.0) |